212 - References

References

Schizophrenia and related psychoses CHAPTER 1 Summary Antipsychotics are almost certainly associated with a small but important increased risk of venous thromboembolism and associated hazards of pulmonary embolism, stroke and myocardial infarction. Risk appears to be greatest during the early part of treatment and in younger people and is probably dose-related. Practice points ■ ■Monitor closely all patients (but especially younger patients) starting antipsychotic treatment for signs of venous thromboembolism: ■ ■calf pain or swelling ■ ■sudden breathing difficulties ■ ■signs of myocardial infarction (chest pain, nausea, etc.) ■ ■signs of stroke (sudden unilateral weakness, etc.). ■ ■Use the lowest therapeutic dose. ■ ■Encourage good hydration and physical mobility. References

1. Häfner H, et al. Thromboembolic complications in neuroleptic treatment. Compr Psychiatry 1965; 6:25–34.
2. Zornberg GL, et al. Antipsychotic drug use and risk of first-­time idiopathic venous thromboembolism: a case-­control study. Lancet 2000; 356:1219–1223.
3. Zhang R, et al. Antipsychotics and venous thromboembolism risk: a meta-­analysis. Pharmacopsychiatry 2011; 44:183–188.
4. Barbui C, et al. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-­analysis of observational studies. Drug Saf 2014; 37:79–90.
5. Ishiguro C, et  al. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case–control study using the CPRD. Pharmacoepidemiol Drug Saf 2014; 23:1168–1175.
6. Wang MT, et al. Use of antipsychotics and risk of venous thromboembolism in postmenopausal women: a population-­based nested case– control study. Thromb Haemost 2016; 115:1209–1219.
7. Letmaier M, et al. Venous thromboembolism during treatment with antipsychotics: results of a drug surveillance programme. World J Biol Psychiatry 2018; 19:175–186.
8. Parker C, et al. Antipsychotic drugs and risk of venous thromboembolism: nested case–control study. BMJ 2010; 341:c4245.
9. Di X, et al. Antipsychotic use and risk of venous thromboembolism: a meta-­analysis. Psychiatry Res 2021; 296:113691.
10. Liu Y, et al. Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-­ analysis of observational studies. Ther Adv Psychopharmacol 2021; 11:2045125320982720.
11. Hagg S, et al. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf 2009; 8:537–547.
12. Dietrich-­Muszalska A, et al. The first-­ and second-­generation antipsychotic drugs affect ADP-­induced platelet aggregation. World J Biol Psychiatry 2010; 11:268–275.
13. Tromeur C, et al. Antipsychotic drugs and venous thromboembolism. Thromb Res 2012; 130 Suppl 1:S29–S31.
14. Zheng C, et al. Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications. Ther Adv Psychopharmacol 2023; 13:20451253231200257.
15. Zhang Y, et al. New role of platelets in schizophrenia: predicting drug response. Gen Psychiatr 2024; 37:e101347.
16. Ferraris A, et  al. Antipsychotic use among adult outpatients and venous thromboembolic disease: a retrospective cohort study. J Clin Psychopharmacol 2017; 37:405–411.
17. Manoubi SA, et  al. Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-­analysis. Asian J Psychiatr 2022; 73:103105.
18. Zivkovic S, et al. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-­analysis. BMC Psychiatry 2019; 19:189.
19. Papola D, et al. Antipsychotic use and risk of life-­threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand 2019; 140:227–243.